Neogenomics Inc Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)1.50 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $17.78Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $2.3B Enterprise Value $2.5B Shares Outstanding 129.8M diluted Moat Rating None Next Earnings Date27 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary NeoGenomics is successfully transitioning from a legacy, commodity-focused diagnostic provider into a high-value precision oncology platform. The core clinical business is demonstrating robust momentum, driven by above-market Next-Generation Sequencing (NGS) growth and the commercial rollout of high-margin assays like RaDaR ST and PanTracer LBx. While the company continues to report GAAP net losses, its operational efficiency is improving, as evidenced by expanding Adjusted EBITDA margins and a clear path toward positive free cash flow in 2026. The stock trades at a significant discount to its high-growth molecular diagnostics peers, offering an attractive risk-reward profile. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$16.00 Mean target$19.72 High · most bullish analyst$35.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $16.0020% Persistent softness in the pharma services segment continues to drag down consolidated margins, while competitive pressures in the MRD space from well-funded players like Natera and Guardant Health slow the adoption of RaDaR ST. Delays in incremental reimbursement approvals keep the company free cash flow negative through 2026. Base CaseCentral scenario $19.7250% Matches the consensus meanNeoGenomics delivers on its raised full-year 2026 revenue guidance of $797M to $803 million, supported by steady double-digit clinical growth and stable NGS momentum. Adjusted EBITDA reaches the guided range of $55M to $57 million, and the company achieves breakeven to slightly positive free cash flow by late 2026. Bull CaseUpside scenario $35.0030% Rapid commercial adoption of RaDaR ST and PanTracer LBx, supported by expanded Medicare coverage and Epic Aura integration, drives clinical revenue growth above 15% YoY. Operational leverage accelerates, pushing Adjusted EBITDA margins past 10% and generating substantial positive free cash flow, leading to a strong valuation re-rating. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |